focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks make headway amid weak China data

Mon, 15th Aug 2022 17:00

(Alliance News) - Stocks in London struggled on Monday, but managed to end higher, even as China's central bank slashed key interest rates as a raft of data showed weakness in the world's second-largest economy.

The PBoC on Monday sliced the medium-term lending rate to 2.75%, a reduction of 10 basis points. The interest rate is used a benchmark for one-year loans provided to the banking system.

The move came after factory output and retail sales in China edged up in July but were weaker than analysts' expectations, as a Covid-19 resurgence and property market jitters cast a pall over hopes for a stronger economic recovery.

The world's second-biggest economy saw a bounce in business activity as some coronavirus restrictions eased in June, but the boost is fading and Beijing remains welded to a zero-Covid policy of snap lockdowns and long quarantines, which has battered sentiment.

But for July, China's industrial production rose 3.8% on-year, down from a 3.9% jump in June, the National Bureau of Statistics said Monday. This undershot market expectations, cited by FXStreet, for growth to speed up to 4.6%.

Retail sales grew at a slower-than-expected 2.7% from a year ago, down from 3.1% in June, while the urban unemployment rate fell to 5.4%, the NBS said. Retail sales had been expected to rise 5%, cited by FXStreet.

The FTSE 100 index closed up 8.26 points, or 0.1%, at 7,509.15. The FTSE 250 closed up 43.80 points, or 0.2%, at 20,382.76, and the AIM All-Share closed up 0.91 of a point at 934.11.

The Cboe UK 100 ended up 0.1% at 749.94. The Cboe UK 250 closed down 0.1% at 17,684.28. The Cboe Small Companies ended flat at 14,472.95.

In European equities, the CAC 40 in Paris ended up 0.3%, while the DAX 40 in Frankfurt ended up 0.2%.

CMC Markets analyst Michael Hewson said: "Basic resources and energy sector have borne the brunt of today's uncertainty after [China's] July industrial production and retail sales both came in well below expectations. The bigger surprise is why anyone is surprised by this given China's reluctance to relax its zero-covid policy, a policy that is likely to weigh on economic growth even more as we head into the winter months.

"As the weather gets colder it's unlikely that infection rates will go down, which means economic activity is likely to remain subdued, and consumer demand will remain weak. In response to today's data China's central bank cut its medium-term lending rate by 10bps, to 2.75%, in a vain attempt to stimulate demand."

In the FTSE 100, RS Group ended the best performer, up 5.0% at 1,142.38 pence, after the Times reported at the weekend that the electrical parts maker could be the subject of a takeover bid.

The Times reported that there has been "chat" that there may be a GBP15-a-share bid imminently. This would be a significant premium to the present price and above the GBP12.35 high the company, formerly known as Electrocomponents, hit last November before worries about recession surfaced.

However, the report did not name any potential suitor.

AstraZeneca closed up 2.2% after it said, alongside partner Daiichi Sankyo, that their Enhertu drug met its primary endpoint in a breast cancer trial.

The Cambridge-based pharmaceutical firm said a form of breast cancer in patients treated with Enhertu showed slowed disease progression. The trial involved sufferers of human epidermal growth factor receptor 2-positive unresectable and/or metastatic breast cancer. Participants had been previously treated with trastuzumab emtansine, an existing cancer therapy.

At the other end of the large-caps, miners were among the worst performers following the disappointing China data. Antofagasta closed down 1.5%, Anglo American down 2.4%, Rio Tinto down 2.2% and Glencore down 1.4%.

Meanwhile, Rio Tinto reiterated its proposal to acquire full-ownership of Turquoise Hill Resources for CAD34 per share, around USD25.48.

The announcement comes after Turquoise Hill said earlier in the day that it was no longer considering Rio Tinto's takeover offer. The Canadian miner said Rio Tinto's offer did not "fully and fairly reflect the fundamental and long-term strategic value" of its majority ownership in the Oyu Tolgoi copper-gold project in Mongolia.

As a result, the company said it was not in the best interest of the company or its shareholders to support Rio Tinto's proposal. Rio Tinto said it was "disappointed" by the decision and asserted that the terms of its proposal would deliver "compelling value" for Turquoise Hill.

In March, the FTSE 100-listed miner announced it was proposing to acquire the remaining 49% of Turquoise Hill that it does not currently own. This represented a 32% premium to the firm's closing price on the Toronto Stock Exchange at the time.

Oil majors BP and Shell closed down 1.2% and 1.5% respectively, tracking spot oil prices lower.

Brent oil was quoted at USD94.22 a barrel at the equities close, down sharply from USD97.91 at the close Friday.

In the FTSE 250, Auction Technology ended the worst performer, down 4.7%, after JPMorgan downgraded the platform to 'neutral' from 'overweight'.

The pound was quoted at USD1.2075 at the London equities close, down from USD1.2121 at the close Friday.

The euro stood at USD1.0184 at the European equities close, down from USD1.0248. Against the yen, the dollar was trading at JPY133.07, down from JPY133.63.

Stocks in New York were lower at the London equities close. The DJIA was down 0.1%, the S&P 500 index down 0.3% and the Nasdaq Composite down 0.2%.

On Wall Street, Moderna was up 2.5% after the UK's medicines regulator said it had approved an updated version of the drugmaker's vaccine against Covid-19, that targets the Omicron variant as well as the original form of the virus.

The Medicine & Healthcare products Regulatory Agency said it had approved the vaccine for adult booster doses "after it was found to meet the UK regulator's standards of safety, quality and effectiveness".

It was the first such "bivalent" Covid-19 vaccine to be approved by the UK regulator.

Gold stood at USD1,778.71 an ounce at the London equities close, lower against USD1,797.13 late Friday.

The economic events calendar on Tuesday has UK unemployment data at 0700 BST and Germany ZEW indicator of economic sentiment at 1000 BST.

The UK corporate calendar on Tuesday has annual results from miner BHP Group and interim results from Bank of Georgia. Authorised Rolex dealer Watches of Switzerland puts out first-quarter numbers.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
13 Feb 2024 12:06

LONDON MARKET MIDDAY: Stocks fall but pound up before US data

(Alliance News) - Stock prices in London were on the decline on Tuesday afternoon, with sentiment tetchy ahead of a US inflation report later.

Read more
13 Feb 2024 09:32

LONDON BROKER RATINGS: Citi lifts GSK; Shore likes XPS Pensions

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 09:41

LONDON BROKER RATINGS: Deutsche Bank starts Deliveroo at 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
12 Feb 2024 09:12

Barclays sees "compelling" entry point at AstraZeneca after recent falls

(Sharecast News) - Barclays has kept an 'overweight' position on AstraZeneca despite the biopharma group's disappointing annual results last week, saying that the stock's recent underperformance provides an attractive entry point for investors.

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
9 Feb 2024 07:51

LONDON BRIEFING: Barclays buys Tesco's retail banking business

(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.

Read more
8 Feb 2024 17:00

LONDON MARKET CLOSE: Softer earnings weigh on underperforming FTSE 100

(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.

Read more
8 Feb 2024 14:42

London close: Stocks slip as US jobless claims fall

(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.

Read more
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.